Focus on innovative drugs, high-end preparations, specialty APIs, and high-end customized APIs. Accelerate the development of new-structure, new-target, and new-mechanism drugs for treating drug-resistant bacterial infections, tumors, viruses, cardiovascular and cerebrovascular diseases, and neurological and autoimmune diseases.

Focus on expanding and strengthening advantageous varieties. Attract large TCM R&D and production enterprises, promote innovation in TCM, and accelerate the secondary growth of well-known TCM products.

Focus on developing protein and peptide drugs, vaccines, humanized/human monoclonal antibody drugs, cell therapy products such as stem cells, nucleic acid drugs, and gene therapy drugs.

Leverage advanced technologies such as big data, cloud computing, and 3D printing to promote the digitalization of diagnostic and therapeutic equipment. Industrial clusters such as Haicang Biopharmaceutical Port and the Western Fujian (Changting) Medical Equipment Industrial Park can accelerate the development of new products such as in vitro diagnostic instruments, reagents, and health monitoring equipment. Promote the development of new technologies such as high-specificity molecular diagnostics and biochips and foster the high-end medical equipment industry.